Deoxycholic Acid and the Risk of Death and Cardiovascular Events among Patients with Advanced CKD

Background: Circulating levels of the secondary bile acid, deoxycholic acid (DCA), are elevated in chronic kidney disease (CKD) and may contribute to vascular calcification in CKD patients. Whether circulating DCA levels are associated with death and cardiovascular events (CVE) among advanced chronic kidney disease patients is unknown. Methods: TheHomocysteine Study was a randomized double-blind trial evaluating the effects of high doses of folic acid and B vitamins on all-cause mortality (ACM) and CVE in subjects with advanced CKD and elevated serum homocysteine levels. Fasting serum DCA levelswere measured in stored serum samples obtained at 3 months in a cohort of 1,054 patients with mainly stage 4 CKD (mean eGFR 18.1± 6.5 mL/min/1.73m2). The study population was divided into quartiles according to plasma DCA levels. We used Cox proportional-hazards models to examine the association between DCE levels with ACM and a composite of CVE (combining myocardial infarction, stroke, and amputation). Results: Participants had a mean age of 69±11 years. The median DCA level was 119 [63-232] ng/mL. During a median follow-up of 3.0 years, 445 (42%) patients died from any cause and 210 (20%) had a CVE. Higher DCA levels were not associated with higher risks of death. Compared to the first (lowest) quartile, the HR (95% CI) for death were as follows: second quartile, 0.89 (0.74-1.06); third quartile, 0.98 (0.82-1.18) and fourth quartile, 0.88 (0.73-1.06) after adjustment for potential confounders available in the database. Similar results were obtained when DCA was examined as a continuous variable: 0.97 (0.93-1.02). Compared to the lowest quartile, the two highest quartiles of DCA were also not associated with a significantly elevated risk of CVE (HR 0.98, 95% CI 0.82-1.78) and (HR 0.87, 95%CI 0.73-1.05), respectively after multivariate adjustment. Conclusion: Among HOST participants, DCA was not associated with death and cardiovascular events in patients with advanced CKD not requiring dialysis. Funding: Veterans Affairs Support

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024f17q4qkv
Primary Topic
Eicosanoids and Hypertension Pharmacology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deoxycholic Acid and the Risk of Death and Cardiovascular Events among Patients with Advanced CKD

Kristen L. Nowak, Shinobu Miyazaki‐Anzai, Makoto Miyazaki, Jiang Gu et al.
Journal of the American Society of Nephrology
Eicosanoids and Hypertension Pharmacology
article

Deoxycholic Acid and the Risk of Death and Cardiovascular Events among Patients with Advanced CKD

Kristen L. Nowak, Shinobu Miyazaki‐Anzai, Makoto Miyazaki, Jiang Gu, Anna Jovanovich, Michel Chonchol, Caitlin Hoffman
article en

Abstract

Background: Circulating levels of the secondary bile acid, deoxycholic acid (DCA), are elevated in chronic kidney disease (CKD) and may contribute to vascular calcification in CKD patients. Whether circulating DCA levels are associated with death and cardiovascular events (CVE) among advanced chronic kidney disease patients is unknown. Methods: TheHomocysteine Study was a randomized double-blind trial evaluating the effects of high doses of folic acid and B vitamins on all-cause mortality (ACM) and CVE in subjects with advanced CKD and elevated serum homocysteine levels. Fasting serum DCA levelswere measured in stored serum samples obtained at 3 months in a cohort of 1,054 patients with mainly stage 4 CKD (mean eGFR 18.1± 6.5 mL/min/1.73m2). The study population was divided into quartiles according to plasma DCA levels. We used Cox proportional-hazards models to examine the association between DCE levels with ACM and a composite of CVE (combining myocardial infarction, stroke, and amputation). Results: Participants had a mean age of 69±11 years. The median DCA level was 119 [63-232] ng/mL. During a median follow-up of 3.0 years, 445 (42%) patients died from any cause and 210 (20%) had a CVE. Higher DCA levels were not associated with higher risks of death. Compared to the first (lowest) quartile, the HR (95% CI) for death were as follows: second quartile, 0.89 (0.74-1.06); third quartile, 0.98 (0.82-1.18) and fourth quartile, 0.88 (0.73-1.06) after adjustment for potential confounders available in the database. Similar results were obtained when DCA was examined as a continuous variable: 0.97 (0.93-1.02). Compared to the lowest quartile, the two highest quartiles of DCA were also not associated with a significantly elevated risk of CVE (HR 0.98, 95% CI 0.82-1.78) and (HR 0.87, 95%CI 0.73-1.05), respectively after multivariate adjustment. Conclusion: Among HOST participants, DCA was not associated with death and cardiovascular events in patients with advanced CKD not requiring dialysis. Funding: Veterans Affairs Support

Journal of the American Society of NephrologyVol. 35(10S)
University of Colorado Anschutz Medical Campus (US)
Good health and well-being
Openalex Percentile: Top 80%
Eicosanoids and Hypertension Pharmacology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.